// App-Quantinova.ai

1822 : Emergence of MET D1228N mutation as a resistance mechanism following an exceptional response to crizotinib in a MET-amplified triple-negative breast cancer patient

Researchers

Presenter

  • Benjamin M. Parsons

Principal Investigators

  • David R. Meier

  • Grzegorz T. Gurda

  • Kristopher A. Lofgren

  • Paraic A. Kenny

Medical Centers

  • Gundersen Medical Foundation, La Crosse, WI.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Hepatocyte growth factor receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Cabozantinib

  • Capecitabine

  • Carboplatin

  • Doxorubicin

  • Paclitaxel

  • Crizotinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved